Walgreens Boots Alliance Inc.

---

ticker: WBA step: 01 generated: 2026-05-12 source: quick-research

Walgreens Boots Alliance, Inc. (WBA) — Business Overview

⚠️ STATUS: NO LONGER PUBLICLY TRADED

Sycamore Partners completed acquisition August 28, 2025. WBA delisted from NASDAQ. Operates as private company split into 5 standalone businesses: Walgreens, The Boots Group, Shields Health Solutions, CareCentrix, and VillageMD.

Business Description (pre-take-private)

Walgreens Boots Alliance was one of the world's largest retail pharmacy chains and the first global pharmacy-led, health and wellbeing enterprise. WBA operated ~12,500 stores across the US (Walgreens) + Europe + Asia (Boots, Benavides, Ahumada) before take-private. Filed major restructuring under CEO Tim Wentworth (Nov 2023) including 1,200+ store closures + VillageMD divestiture.

Revenue Model (pre-take-private)

~$150B FY2024 (fiscal year ending Aug 2024) revenue across three segments: U.S. Retail Pharmacy (~80%, prescriptions + front-store retail), International (~15%, Boots UK + others), U.S. Healthcare (~5%, VillageMD primary care, Shields, CareCentrix). PBM-reimbursed prescription revenue dominant. Front-store retail (cosmetics, beauty, food, OTC) increasingly pressured.

Products & Services (pre-take-private)

• Walgreens US retail pharmacy — ~8,000 stores; prescription + OTC + beauty + photo
• Boots UK + International — ~2,000 stores Boots UK + Benavides Mexico + Ahumada Chile
• VillageMD — Primary care clinics co-located in Walgreens (divested in process)
• Shields Health Solutions — Specialty pharmacy services (divested in process)
• CareCentrix — Post-acute home health (divested in process)
• Owned brands — Boots No.7, Soap & Glory, Liz Earle (Boots UK)

Customer Base & Go-to-Market (pre-take-private)

~110M Walgreens app users; ~70M MyWalgreens members. Front-store consumer shopper increasingly losing to Amazon + dollar stores + mass retail (Target, Walmart). Pharmacy customers: ~80%+ insured (PBM-reimbursed). 24M Boots Advantage Card members in UK.

Sycamore Partners Take-Private Deal Structure

• Total transaction value: up to $23.7B
• Shareholders received: $11.45/share cash + 1 non-transferable right (up to $3.00 from VillageMD monetization)
• Closed: August 28, 2025
• Stefano Pessina (largest shareholder): 100% reinvest interests
• Post-deal structure: 5 standalone private companies

Key Facts

• Founded: 1901 (Walgreens); 2014 (WBA merger Walgreens + Alliance Boots)
• Headquarters: Deerfield, IL (pre-deal)
• Employees: ~330,000 (pre-deal)
• Exchange: NASDAQ (WBA — delisted August 28, 2025)
• Sector / Industry: Consumer Staples / Drug Retail
• Status: PRIVATE (no longer publicly traded)

---

ticker: WBA step: 04 generated: 2026-05-12 source: quick-research

Walgreens Boots Alliance (WBA) — Financial Snapshot

⚠️ STATUS: NO LONGER PUBLICLY TRADED

WBA delisted from NASDAQ August 28, 2025 following Sycamore Partners $23.7B take-private acquisition.

Income Statement Summary (pre-take-private)

Metric	FY2022	FY2023	FY2024	FY2025E
Revenue	$132.7B	$139.1B	$147.7B	$150.4B
U.S. Retail Pharmacy Comp Sales	–	-1%	-1.7%	-4% to -5%
Net Income (GAAP)	$4.34B	-$3.08B	-$8.6B	–
Adjusted EPS	$5.04	$3.98	$2.88	$1.40-1.80 (guide)

Fiscal year ends August. FY24 GAAP -$8.6B reflects $12B goodwill impairment + VillageMD charges. Adj EPS deteriorating from $5+ peak to $1.40-1.80 guide for FY25.

Cash Flow & Balance Sheet (pre-take-private, FY2024)

Metric	Value
Operating Cash Flow	~$1.0B (vs ~$2.3B FY23)
Free Cash Flow	~$0.4B
Cash & Equivalents	~$0.7B
Total Debt	~$12B+
Net Debt/EBITDA	Elevated

Final Take-Private Terms (Aug 28, 2025)

• Sycamore Partners acquired WBA for $11.45/share + up to $3.00 contingent value right
• Total transaction value: up to $23.7B (including debt)
• VillageMD CVR backed by future divestiture proceeds (estimated ~$2.7B total)

Sycamore's Operating Plan (2026+)

• Aggressive surgical removal of unprofitable assets
• Already closed >500 of 1,200 targeted stores by early 2026
• Massive corporate layoffs
• Five separate operating companies
• No public financial reporting going forward

---

ticker: WBA step: 12 generated: 2026-05-12 source: quick-research

Walgreens Boots Alliance (WBA) — Investment Catalysts & Risks

⚠️ STATUS: NO LONGER PUBLICLY TRADED — STOCK DELISTED

WBA was acquired by Sycamore Partners and delisted from NASDAQ on August 28, 2025. The ticker is no longer investable.

Historical Context

Sycamore Partners completed its $23.7B take-private acquisition of Walgreens Boots Alliance on August 28, 2025. Shareholders received $11.45/share cash plus a contingent value right (CVR) of up to $3.00/share tied to future monetization of WBA's VillageMD interests. Following the deal close, WBA's common stock ceased trading on Nasdaq.

Reasons for Take-Private

1. Severe pharmacy economics deterioration — PBM reimbursement rates squeezed pharmacy margins below cost in many cases. US Retail Pharmacy comp sales declining 4-5% in FY25. Adj EPS fell from $5+ peak (FY22) to $1.40-1.80 guide (FY25) — 70% decline in 3 years.

2. VillageMD failed diversification — $12B+ writedowns — Walgreens' $5.2B investment in VillageMD (2021) failed to generate expected returns. Goodwill impairments + writedowns totaled $12B+ over 2023-24. Strategic pivot from pharmacy to primary care provider proved costly.

3. Amazon Pharmacy + retail competition — Amazon Pharmacy's expansion + PillPack integration captured high-margin chronic medication market. CVS + Walgreens "retreating" from physical footprint creating "pharmacy deserts." Front-store retail compressed by Amazon + dollar stores + mass retail.

4. Public market valuation collapsed — Stock fell from $90+ (2015 peak) to ~$8-10 (2024-25) — 90%+ decline. Public market unable/unwilling to fund prolonged turnaround. Stefano Pessina (founding shareholder) supported take-private path.

Sycamore's Restructuring Strategy (2026+)

• 5 standalone companies: Walgreens (US retail pharmacy), The Boots Group (UK + international), Shields Health Solutions, CareCentrix, VillageMD
• Aggressive store closures: 500+ of 1,200 targeted stores already closed by early 2026
• Corporate layoffs: Significant workforce reductions
• VillageMD divestiture: Full sale or asset-level monetization to fund CVR
• Private equity playbook: Cost cuts → operational turnaround → eventual re-IPO or strategic sale in 5-7 years

What This Means for Investors

• Public investors: Position closed at $11.45/share + outstanding CVR rights for VillageMD monetization
• CVR holders: Can receive up to $3.00/share if VillageMD divestiture proceeds exceed thresholds
• No future earnings reports: WBA is now private; no public financial visibility
• Sector implications: CVS Health (CVS) remains the only major public retail pharmacy chain; takeaway lesson for retail pharmacy industry economics

Research Date

Generated: 2026-05-12

Note: This research file is historical reference only. WBA is no longer publicly traded.